Navigation Links
For Treatment of Extensive-Disease Small-Cell Lung Cancer (ED-SCLC), No Emerging Therapy is Likely to Replace Etoposide/Carboplatin as the Standard of Care Before 2022
Date:4/23/2013

BURLINGTON, Mass., April 23, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the numerous therapies in clinical development for extensive-disease small-cell lung cancer (ED-SCLC), no emerging therapy is likely to replace etoposide (Bristol-Myers Squibb's Etopophos/VePesid, generics)/carboplatin (generics) as the standard of care before 2022. Interviewed experts complain that treatment for SCLC has changed very little in decades, and—given the challenges of treating this aggressive disease and the current clinical pipeline—experts are pessimistic that the treatment landscape will improve in the near future.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The DecisionBase 2013 report entitled How Receptive Would Oncologists and Payers Be to Therapies That Partially Address the Unmet Needs of Patients with Advanced Disease? finds that surveyed U.S. and European oncologists agree that increasing overall survival (OS) is one of the greatest unmet needs in ED-SCLC. Despite high response rates with first-line therapy, most patients relapse within a year after treatment and survival rates remain dismal. Experts admit that, should efficacy benefits be seen with therapies in development—such as Ziopharm Oncology's Zymafos, Bristol-Myers Squibb's Yervoy, Genentech/Roche/Chugai's Avastin or Immunogen's lorvotuzumab mertansine—these benefits will likely be only incremental improvements that will not transform current treatment practice. According to the findings, a drug that offers marked improvement in survival presents a strong commercial opportunity to developers, although no drug in clinical development is expected to imp
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
3. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
5. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
8. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argoss Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... July 6, 2015 E-QURE Corp (OTCQB: EQUR), ... live at VirtualInvestorConferences.com on July 9, 2015. ... http://tinyurl.com/e-qure-presentation This will be a ... ask the company questions in real-time - both in ... trade booth." If attendees are not able to join ...
(Date:7/6/2015)... July 6, 2015 Array BioPharma,s (NASDAQ: ... this past weekend at the 2015 ESMO World ... At the meeting, data were shared from a ... 100-patient randomized Phase 2 expansion of that trial ... EGFR inhibitor, with or without the addition of ...
(Date:7/6/2015)... and SOUTH SAN FRANCISCO, Calif. ... (NYSE: AGN ), a leading global pharmaceutical company, ... developing novel treatments for dry eye disease, today announced ... Allergan will acquire Oculeve in an all-cash transaction.  Under ... for a $125 million upfront payment and commercialization milestone ...
Breaking Medicine Technology:E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4
... JERUSALEM, Jan. 11 IDenta Corp. (PinkSheets: IDTA) announced today ... a General Screening Explosive Identifier. , This kit has been ... ampoules it contains, the following substances can be identified with ... Identifier.. , Ampoule 1: TNT, DNT, Tetryl. , Ampoule ...
... LAGUNA BEACH, California, January 11 Advanced ... announced today that it has completed a $5 million ,Series,B, ... venture,capital firm specialized in medical technology investments, and is expected,to ... was founded in 2007 to develop a novel irrigated radiofrequency,cardiac ...
Cached Medicine Technology:International Drug & Explosives Detection Firm IDenta Corp Announces that the TNT/PETN/RDX/NITRATE Test Kit can be used as a General Screening Explosive Identifier 2International Drug & Explosives Detection Firm IDenta Corp Announces that the TNT/PETN/RDX/NITRATE Test Kit can be used as a General Screening Explosive Identifier 3Advanced Cardiac Therapeutics Completes $5 Million Financing 2Advanced Cardiac Therapeutics Completes $5 Million Financing 3
(Date:7/6/2015)... ... July 06, 2015 , ... ... $400,000 in grant funds to support a three-year effort to reduce rates of ... will be conducted in partnership with the Morehouse School of Medicine’s Prevention Research ...
(Date:7/6/2015)... ... July 06, 2015 , ... Orthopaedic & ... his 100th case using SpineFrontier’s® PedFuse® REmind® Screws. The operation took place on ... VA. The procedure was an L5-S1 posterior lumbar interbody fusion on a 69 ...
(Date:7/5/2015)... ... July 06, 2015 , ... ... market, is excited to announce the next generation of PrimeStar Individual Dental Insurance. ... to now include two network options—Maximum Allowable Charge (MAC) and usual, customary and ...
(Date:7/5/2015)... ... 2015 , ... Women’s Excellence in Wellness, powered by Movestrong is ... special consists of 2 months of unlimited classes for just $65. Student ID is ... 1410 South Lapeer Road in Lake Orion. , Women’s Excellence is ...
(Date:7/4/2015)... NY (PRWEB) , ... July 04, 2015 , ... Chronic ... 15% of chronic pain sufferers have pain located in the neck. Another 19% suffer ... the neck. Chiropractic literature suggests that 45% of American workers must deal ...
Breaking Medicine News(10 mins):Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2Health News:New Advancement in Treatment of Chronic Neck Pain 2Health News:New Advancement in Treatment of Chronic Neck Pain 3
... Moms and Babies, Bad for Mercury Fear,Campaign, WASHINGTON, ... for pregnant women, issued this morning by,the National Healthy ... at the nonprofit Center for Consumer Freedom,made the following ... and mercury swung back in the,direction of common sense. ...
... a departure from,current FDA and EPA guidelines, an ... childbearing age to increase their seafood,consumption, despite the ... other contaminants commonly found in seafood., "It,s ... fish without,mentioning the documented public health risks associated ...
... PRINCETON, N.J., Oct. 4 The following is a,statement ... their health information online:, It is encouraging that ... develop personal health record (PHR) products and systems,that people ... we,hope more companies will follow suit. Having ready access ...
... fired for managing diabetes at work but whose ... before House Judiciary,Subcommittee about his experience, ALEXANDRIA, ... reiterated its strong support for the ADA,Restoration Act, ... landmark,1990 Americans with Disabilities Act. On Thursday, the ...
... Psychemedics Corporation,(AMEX: PMD ) today announced that ... Controller. Jennifer will be responsible for all ... the financial analysis and planning,activities necessary for the ... Chairman and CEO. Since 1999, Jennifer has ...
... My Diabetes Connector, provides patients with virtual diabetes health- ... ... The American,Diabetes Association today unveiled a new web-based diabetes tool ... care providers -- to,share and organize important health information to ...
Cached Medicine News:Health News:Consumer Group Statement on Seafood and Health: 'We Told You So' 2Health News:Statement Regarding Microsoft's Announcement of New Services to Help People Store Their Health Information Online 2Health News:American Diabetes Association Urges Congress to Pass ADA Restoration Act, Help End Employment Discrimination Against Americans with Diabetes 2Health News:American Diabetes Association Urges Congress to Pass ADA Restoration Act, Help End Employment Discrimination Against Americans with Diabetes 3Health News:Jennifer Chmieleski Joins Psychemedics Corporation as Top Financial Officer 2Health News:New Diabetes Tool Available on American Diabetes Association Web Site 2Health News:New Diabetes Tool Available on American Diabetes Association Web Site 3Health News:New Diabetes Tool Available on American Diabetes Association Web Site 4
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
For connection to the bipolar output of electrosurgical generators....
This table has an adjustable height, two legs, and square post. Clamps and standard 1" (2.5 cm) pad included....
... for orthopedic procedures. Molded armrests ... 24" for the surgeon's comfort. ... to any O.R. table. Split ... and stability. Optional post or ...
Medicine Products: